Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.14 (
ATP synthase
)
7,042
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have designed and synthesized both the quinoline and naphthalene based molecules influenced by the unique structural make-up of mefloquine and TMC207, respectively. These compounds were evaluated for their anti-mycobacterial activity against drug sensitive Mycobacterium tuberculosis H37Rv in vitro at single-dose concentration (6.25 microg/mL). The compounds 22, 23, 26 and 27 inhibited the growth of M. tuberculosis H37Rv 99%, 90%, 98% and 91% respectively. Minimum inhibitory concentration of compounds 22, 23, 26 and 27 was found to be 6.25 microg/mL. Our molecular modeling and docking studies of designed compounds showed hydrogen bonding with Glu-61, Tyr-64 and Asn-190 amino acid residues at the putative binding site of
ATP synthase
, these interactions were coherent as shown by Mefloquine and TMC207, where hydrogen bonding was found with Tyr-64 and Glu-61 respectively.
SAR
analysis indicates importance of hydroxyl group and nature of substituents on piperazinyl-phenyl ring was critical in dictating the biological activity of newly synthesized compounds.
...
PMID:Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. 2013 35
The emergence of drug resistance in infectious microbial strains can be overcome by development of novel drug molecules against unexploited microbial target. The success of Bedaquiline in recent years, as F
o
F
1
ATP synthase
inhibitor against XDR and MDR mycobacterium strains, has resulted in further exploration to identify more potent and safe drug molecules against resistant strains. F
o
F
1
ATP synthase
is the main energy production enzyme in almost all eukaryotes and prokaryotes. Development of bacterial
ATP synthase
inhibitors is a safe approach, without causing harm to mammalian cells due to structural difference between bacterial and mammalian
ATP synthase
target sites. This review emphasizes on providing the structural insights for F
o
F
1
ATP synthase
of different prokaryotes and will help in the design of new potent antimicrobial agents with better efficacy. Further, applications of synthetic and natural active antimicrobial
ATP synthase
inhibitors, reported by different research groups are summarized. Their
SAR
and mode of actions are also analysed.
...
PMID:Recent advancements in mechanistic studies and structure activity relationship of F
o
F
1
ATP synthase inhibitor as antimicrobial agent. 3149 45